Vor Biopharma (VOR) Free Cash Flow (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Free Cash Flow data on file, last reported at -$38.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 23.27% year-over-year to -$38.3 million in Q1 2026; TTM through Mar 2026 was -$150.9 million, a 50.32% decrease from a year earlier, with the FY2025 full-year figure at -$143.7 million, down 43.81% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$38.3 million, down from -$23.1 million in the prior quarter.
• Over the last five years, Free Cash Flow for VOR reached as high as -$11.1 million in Q3 2022 and fell as low as -$53.9 million in Q3 2025.
• Historically, Free Cash Flow has averaged -$27.5 million across 5 years, with a median of -$24.6 million in 2023.
• Across the five-year window, Free Cash Flow surged 44.22% in 2022 and tumbled 155.18% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$18.3 million in 2022, then fell by 26.24% to -$23.1 million in 2023, then slipped by 4.31% to -$24.1 million in 2024, then climbed by 4.23% to -$23.1 million in 2025, then slumped by 65.67% to -$38.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$38.3 million in Q1 2026, -$23.1 million in Q4 2025, and -$53.9 million in Q3 2025.